paclitaxel has been researched along with Rhabdomyosarcoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Brancale, A; Chen, F; Coluccia, A; Costa, B; Da Pozzo, E; Di Cesare, E; Dondio, G; Famiglini, V; Granata, I; Hamel, E; Iannitto, ML; La Regina, G; Lavia, P; Li, J; Maresca, B; Martini, C; Mercurio, C; Miranda Cona, M; Nalli, M; Ni, Y; Novellino, E; Pelliccia, S; Piscitelli, F; Porta, A; Reggio, A; Rensen, WM; Santoni, A; Silvestri, R; Soriani, A; Varasi, M; Vultaggio, S | 1 |
| Aschero, R; Balaguer-Lluna, L; Baulenas-Farres, M; Burgueño, V; Carcaboso, AM; Castillo-Ecija, H; Cuadrado-Vilanova, M; de Alava, E; Lavarino, C; Martinez-Velasco, N; Mora, J; Olaciregui, NG; Pascual-Pasto, G; Perez-Jaume, S; Resa-Pares, C; Tirado, OM; Vila-Ubach, M | 1 |
| Amoroso, L; Bisogno, G; Casanova, M; Castel, V; Chen, N; Chisholm, JC; Doz, F; Fagioli, F; Gerber, NU; Hingorani, P; le Bruchec, Y; Marquez-Vega, C; Melcón, SG; Moreno, L; Ruggiero, A; Simcock, M; Slepetis, R; Vassal, G | 1 |
| Baruchel, S; Elias, E; Kumar, S; Leadley, M; Marrano, P; Thorner, P; Zhang, L | 1 |
| Billups, CA; Cheshire, PJ; Creech, J; Favours, E; Houghton, PJ; Lee, FY; Peterson, JK; Smykla, R; Tucker, C | 1 |
| Bensussan, A; Bizzini, B; Gallo, RC; Genne, P; Larcier, P; Le Buanec, H; Paturance, S; Rad, FH; Ryffel, B; Uzan, G; Zagury, D | 1 |
1 trial(s) available for paclitaxel and Rhabdomyosarcoma
| Article | Year |
|---|---|
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Topics: Adolescent; Age Factors; Albumins; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Europe; Female; Humans; Infant; Male; Neuroblastoma; Paclitaxel; Progression-Free Survival; Rhabdomyosarcoma; Sarcoma, Ewing; Time Factors; Tissue Distribution; Young Adult | 2020 |
5 other study(ies) available for paclitaxel and Rhabdomyosarcoma
| Article | Year |
|---|---|
Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imidazoles; Indoles; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice; Microsomes, Liver; Mitosis; Permeability; Polymerization; Pyridines; Reactive Oxygen Species; Rhabdomyosarcoma; Solubility; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2013 |
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
Topics: Antineoplastic Agents; Biomarkers; Bone Neoplasms; Child; Humans; Osteonectin; Paclitaxel; Rhabdomyosarcoma; Sarcoma, Ewing | 2023 |
Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasms; Neuroblastoma; Osteosarcoma; Paclitaxel; Rhabdomyosarcoma; Xenograft Model Antitumor Assays | 2013 |
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Topics: Animals; Area Under Curve; Brain Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Epothilones; Female; Humans; Maximum Tolerated Dose; Mice; Mice, SCID; Microtubules; Mitosis; Models, Chemical; Neoplasm Transplantation; Neuroblastoma; Osteosarcoma; Paclitaxel; Rhabdomyosarcoma; Time Factors; Treatment Outcome; Vinca Alkaloids; Wilms Tumor | 2005 |
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
Topics: Animals; Antibodies; Antibody Formation; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Female; HT29 Cells; Humans; Immune Sera; Immunization; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Rhabdomyosarcoma; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |